Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of products with price leadership amid rising costs in the supply chain due to geopolitical tensions and policy changes affecting raw material prices [2] - The report highlights the significant price increases in pharmaceutical raw materials, particularly vitamins and amino acids, which have seen price increases of 40.54% and 84.66% respectively since the beginning of the year [2] - The report notes the approval of China's first invasive brain-machine interface, marking a significant milestone in the medical device sector [5] - The report indicates a strong trend in China's innovative pharmaceuticals going global, with a notable increase in licensing-out transactions [6] Summary by Sections 1. Supply Chain Dynamics - The report discusses the impact of rising prices in upstream chemical products on pharmaceutical raw materials, stressing that the ability to pass on these costs is crucial for maintaining profitability [2] - It mentions that 90% of monitored products have seen price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] 2. Market Trends in Disposable Gloves - The report details the price increases in disposable nitrile gloves and PVC gloves due to rising costs of raw materials like butadiene and acrylonitrile, which have increased by 84.43% and 47.30% respectively [3] - It notes that the domestic utilization rate for nitrile gloves has improved, and export prices have been rising since late 2025 [3] 3. Regulatory Environment - The report highlights the impact of dual-use item management on the pricing of key materials, creating significant price disparities between domestic and international markets [4] - It suggests that stricter controls on resources like rare earths could enhance the competitive advantage of domestic medical products [4] 4. Innovations in Medical Devices - The report discusses the approval of the brain-machine interface by the National Medical Products Administration, which is expected to open new market opportunities [5] - It outlines the potential for significant market growth in this area, given the high number of spinal cord injury patients in China [5] 5. International Expansion of Chinese Pharmaceuticals - The report notes that there have been 39 licensing-out transactions in the innovative drug sector, with upfront payments totaling approximately $2.953 billion [6] - It emphasizes that the trend of Chinese pharmaceuticals going global continues to strengthen, with a focus on small nucleic acid drugs and dual antibodies [7] 6. Stock Recommendations - The report recommends focusing on raw material suppliers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Inco Medical and Blue Sail Medical in the disposable glove sector [8] - It also suggests monitoring companies involved in the invasive brain-machine interface and small nucleic acid drugs, indicating potential for growth in these areas [8]

重视涨价逻辑演绎；"十五五"规划明确产业方向，看好创新药械 与 AI+机遇 医药生物 证券研究报告/行业定期报告 2026 年 03 月 15 日 执业证书编号：S0740519040001 Email：liuzq04@zts.com.cn | 基本状况 | | | --- | --- | | 上市公司数 | 504 | | 行业总市值(亿元) | 69,254.89 | | 行业流通市值(亿元) | 63,426.67 | 行业-市场走势对比 1、《检验类立项指南征求意见稿印 志物检测列项》2026-03-13 2026-03-09 历》2026-03-08 | 评级： 增持（维持） | | 重点公司基本状况 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 简称 | 股价 | | | EPS | | | | | PE | | | 评级 | | 分析师：祝嘉琦 | | | （元） | 2023A | 2024A ...

Investment Rating - The report maintains an "Overweight" rating for the industry [6] Core Insights - The pharmaceutical sector is experiencing volatility and differentiation, with structural opportunities arising from policy catalysts and performance windows. The Shanghai Composite Index fell by 1.07%, while the pharmaceutical sector dropped by 2.78%, ranking 17th among 31 sub-industries. Notably, the market showed a rebound after initial geopolitical concerns, driven by positive mentions of pharmaceuticals in the government work report [8][14] - The report emphasizes the importance of the upcoming Q1 earnings reports, which are expected to provide positive catalysts, particularly for companies like Ailis, which anticipates a 41% revenue increase and a 44% rise in net profit [8][14] - The government work report highlights the development of emerging industries, including biomedicine, and reiterates the focus on innovative drugs and medical devices. This marks the third consecutive year that "innovative drugs" have been included in the report, indicating a sustained commitment to this sector [8][14] Summary by Sections Market Dynamics - The pharmaceutical sector's performance is influenced by both policy changes and market conditions, with a notable decline in various sub-sectors such as medical services and traditional Chinese medicine [8][14] - The report indicates that the pharmaceutical sector's valuation is currently at 22.4 times PE based on 2026 earnings forecasts, which is a premium of 8.4% compared to the overall A-share market [23] Investment Recommendations - The report suggests focusing on three main investment lines: 1. Leading biotech and biopharma companies that are expected to benefit from improved payment environments and global competitiveness, such as Kangfang Biotech and BeiGene [8][14] 2. Upstream and CXO sectors supported by "patient capital," with companies like WuXi Biologics and Tigermed highlighted as potential beneficiaries [8][14] 3. Cutting-edge fields such as brain-computer interfaces and AI in healthcare, with specific companies recommended for investment [8][14] Company Performance - The report notes that companies in the innovative drug sector have shown strong performance, particularly those with ongoing product developments. Conversely, stocks that previously experienced significant gains are now facing corrections [29]

Investment Rating - The report maintains an "Overweight" rating for the industry [2] Core Insights - The Alzheimer's Disease (AD) sector is transitioning from "symptom improvement" to "disease-modifying therapies (DMT)" in 2026, marking a critical growth phase with the approval of two major amyloid-beta (Aβ) antibody drugs and the emergence of new diagnostic technologies [4][11] - 2026 is expected to be a pivotal year for AD, with significant conferences serving as platforms for academic exchange and market negotiations, focusing on drug administration convenience, the rise of Chinese voices, and the reassessment of diagnostic value [15] - Key drug progress in 2026 includes regulatory decisions on AXS-05 and Leqembi, which could expand the AD treatment market significantly [17] - The AD detection field is set for large-scale clinical adoption, driven by blood tests, AI advancements, and new biomarkers, with a focus on early and precise diagnosis [19] Summary by Sections Industry Overview - The industry comprises 504 listed companies with a total market value of approximately 69,490.56 billion [2] Market Trends - The investment logic is shifting from solely "new drug development" to a comprehensive ecosystem of "early screening + precise treatment + full-course management" [4][11] Key Drug Developments - Major drug approvals and data releases are anticipated throughout 2026, including AXS-05 and Leqembi, which are crucial for market expansion [17][18] Diagnostic Innovations - The trend towards "blood-based" and "intelligent" diagnostics is accelerating, with significant advancements expected in blood biomarkers and AI integration in imaging [19][20] Investment Opportunities - The report highlights the increasing role of Chinese pharmaceutical companies in the global AD landscape, with notable collaborations and innovative drug developments [21][22] Clinical Trials and Research - The domestic clinical pipeline for AD is entering a phase of rapid development, with a focus on precision diagnostics and disease-modifying treatments [24]

Investment Rating - The report maintains a "Buy" rating for several companies including WuXi Biologics, Tigermed, and others, indicating a positive outlook for the sector [3][12][17]. Core Insights - The report emphasizes the importance of focusing on Q1 performance expectations and actively seizing thematic opportunities, particularly in areas like brain-computer interfaces, surgical robots, and AI healthcare [6][15]. - The surgical robot market in China is projected to grow rapidly, with a potential market size exceeding 100 billion yuan by 2033, driven by policy support and increasing clinical demand [10][30]. - The report highlights a strategic focus on the raw material drug sector, which is expected to see a turnaround due to rising prices and the introduction of new business lines such as small nucleic acids and ADCs [7][15]. Summary by Sections Market Performance - In February 2026, the pharmaceutical sector experienced a slight decline of 0.2%, underperforming compared to the Shanghai Composite Index, which rose by 0.1% [6][11]. - The report notes that various sub-sectors within pharmaceuticals, such as traditional Chinese medicine and medical devices, showed positive performance, with increases of 1.49% and 0.93% respectively [6][15]. Surgical Robots - The surgical robot market is on track to reach a scale of 1020.19 billion yuan by 2033, with a compound annual growth rate (CAGR) of 34.3% from 2024 to 2033 [10][23]. - The report discusses the establishment of a unified pricing framework for surgical robots, which is expected to enhance procurement willingness among hospitals [30][31]. Thematic Opportunities - The report suggests focusing on thematic opportunities in brain-computer interfaces, surgical robots, and AI healthcare, particularly as catalysts are expected to materialize soon [6][15]. - Companies such as Innovent Biologics and others are highlighted as key players in the biotech and biopharma sectors, with potential for significant growth [9][16]. Raw Material Drugs - The raw material drug sector is identified as being at a turning point, with expectations of price improvements following several years of decline [7][15]. - Companies like Pro Pharma and others are recommended for their strong business fundamentals and potential for growth in this sector [7][15].

Core Insights - The company is advancing multiple clinical research programs, including Nectin-4 ADC (9MW2821) and B7-H3 ADC (7MW3711), targeting various cancers with promising clinical data and development strategies [1][2][5]. Group 1: Nectin-4 ADC (9MW2821) - Nectin-4 ADC (9MW2821) utilizes a next-generation conjugation technology, MMAE toxin, and DAR4 design, currently in clinical research for urothelial carcinoma, cervical cancer, triple-negative breast cancer, and esophageal cancer [1][4]. - Over 1,900 patients have been enrolled in clinical trials, with several indications progressing ahead of global competitors [1][4]. - Three pivotal Phase III trials are ongoing, with interim analyses planned for 2026, potentially leading to a new drug application meeting with CDE [1][4]. Group 2: B7-H3 ADC (7MW3711) - B7-H3 ADC (7MW3711) has completed Phase II trials, with data presented at the 2025 ESMO conference showing an objective response rate (ORR) of 42.9% for esophageal cancer and 50.0% for small cell lung cancer at a dose of 4.0 mg/kg [2][5]. - The drug demonstrates good tolerability and anti-tumor activity, with a disease control rate (DCR) of 100% for esophageal cancer and 90.0% for small cell lung cancer [2][5]. - The company is pursuing differentiated development strategies, including trials combining 7MW3711 with PD-1/VEGF dual antibodies and platinum-based chemotherapy [6]. Group 3: Small RNA and TCE Platforms - The company has established a small RNA platform focusing on chronic diseases, with the lead candidate 2MW7141 targeting lipid disorders and cardiovascular events, expected to submit IND applications in the US and China this year [3][7]. - The TCE platform features modified CD3 antibodies and secondary signal-activating antibodies, enhancing tumor targeting and reducing off-target effects [8][9]. - 6MW5311, a TCE targeting CD3 and LILRB4, is aimed at treating relapsed/refractory acute myeloid leukemia and is expected to submit IND applications in mid-2026 [9]. Group 4: IL-11 Monoclonal Antibody (9MW3811) - IL-11 monoclonal antibody (9MW3811) is in Phase II trials for pathological scars, with the first patient dosed in December 2025, marking it as the first IL-11 targeted drug for this indication [10]. Group 5: Hong Kong Stock Issuance - The company has submitted an application for H-share issuance on the Hong Kong Stock Exchange and has received a notice for overseas issuance, with the approval process progressing smoothly [11].

Group 1 - The core point of the article is that Maiwei Bio reported a significant increase in total operating revenue for the year 2025, amounting to 662.52 million yuan, which represents a year-on-year growth of 231.62% [2] - The net profit attributable to the parent company for the same period was reported as -970.18 million yuan, indicating a loss [2]

Core Viewpoint - Maiwei Biotech reported significant revenue growth for 2025, with total revenue reaching 663 million yuan, a year-on-year increase of 231.62%. However, the company still recorded a net loss of 970 million yuan, which is an improvement from the previous year's loss of 1.044 billion yuan [1]. Revenue Performance - The company's total revenue for the reporting period was 663 million yuan, marking a substantial increase compared to the previous year [1]. - The revenue growth was primarily driven by significant income recognized from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISC MEDICINE, INC., as well as a notable increase in drug sales revenue compared to the same period last year [1]. Net Loss Analysis - The net loss attributable to the parent company's shareholders was 970 million yuan, which is a reduction from the net loss of 1.044 billion yuan in the same period last year [1].

Financial Performance - Total revenue for 2025 reached RMB 66,251.56 million, a significant increase of 231.62% compared to RMB 19,978.16 million in the previous year[3] - The company's net profit attributable to shareholders was RMB -97,017.55 million, showing a decrease from RMB -104,391.92 million year-on-year[3] - The basic earnings per share were RMB -2.43, slightly improved from RMB -2.61 in the previous year[3] - The weighted average return on net assets dropped by 48.77 percentage points to -99.05% compared to -50.28% in the previous year[3] Assets and Equity - The total assets at the end of the reporting period were RMB 456,784.79 million, reflecting a 6.84% increase from RMB 427,550.89 million at the beginning of the period[3] - The equity attributable to shareholders decreased by 77.78% to RMB 34,866.59 million from RMB 156,887.74 million[3] Revenue Drivers - The increase in total revenue was primarily due to significant income from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISC MEDICINE, INC., along with increased drug sales[5] R&D and Investment - The company maintained high levels of R&D investment as multiple innovative drugs are in critical trial phases, impacting overall financial performance[6] - The decrease in equity and net asset value was attributed to substantial investments in new drug development and increased operating costs due to commercialization efforts[6] Investment Risks - There are no significant uncertainties affecting the accuracy of the financial report, but investors are advised to be cautious regarding investment risks[7]

Investment Rating - The report assigns an "Outperform" rating for the company, indicating a positive outlook for its future performance [4]. Core Insights - The company is positioned as an innovative biopharmaceutical enterprise with a comprehensive industry chain layout and a clear direction for innovation, focusing on unmet clinical needs in oncology and aging-related diseases [2][9]. - The company has established a dual-driven innovation model through self-developed technologies and business development (BD) partnerships, enhancing its pipeline and market presence [2][4]. - The company is actively expanding its product offerings and entering new markets, with a focus on both domestic and international growth strategies [4][21]. Summary by Relevant Sections Company Overview - The company was founded in 2017 and went public on the Shanghai Stock Exchange in 2022, with plans for a Hong Kong listing to support its international expansion [9]. - The management team is experienced, with a stable shareholding structure, ensuring strategic decisions align with the company's core needs [11][13]. Research and Development - The company has multiple R&D platforms, including ADC, TCE, MyoDock™, and small nucleic acids, which work synergistically to achieve innovation and differentiation [22][23]. - The pipeline is rich, focusing on oncology for immediate returns while also developing anti-aging therapies for long-term growth [28]. Business Development Strategy - The company employs a diversified approach to business development, combining internal capabilities with external partnerships to maximize pipeline value [4][19]. - Collaborations with various partners, including local and global firms, are aimed at enhancing product commercialization and expanding market reach [4][21]. Financial Projections and Valuation - Revenue projections for 2025 to 2027 are estimated at 6.74 billion, 11.63 billion, and 12.73 billion RMB, respectively, indicating significant growth potential [4]. - The current market valuation is considered undervalued based on the company's projected cash flow and product pipeline [4]. Product Pipeline Highlights - The core product, Nectin-4 ADC (9MW2821), is in advanced clinical trials for multiple indications, including urothelial carcinoma and cervical cancer, with potential peak sales estimated at 1.988 billion RMB [31][33]. - The company is also developing innovative therapies for Alzheimer's disease and chronic obstructive pulmonary disease, showcasing its commitment to addressing critical health challenges [2][28].